Hope S. Rugo, MD, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses what to do in patients with triple-negative breast cancer who have not achieved a pathological complete response (pCR), an area of unmet need in TNBC. Prof. Rugo discusses strategies currently under evaluation including trials altering treatment in the post-neoadjuvant setting, as well as improving outcomes using novel antibody-drug conjugates. This interview took place at the St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.